| 7.6438 0.025 (0.33%) | 10-24 14:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.83 | 1-year : | 14.05 |
| Resists | First : | 10.13 | Second : | 12.02 |
| Pivot price | 8.31  |
|||
| Supports | First : | 7.07 | Second : | 5.88 |
| MAs | MA(5) : | 7.75 |
MA(20) : | 8.11 |
| MA(100) : | 7.52 |
MA(250) : | 350.94 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 9.1 |
D(3) : | 10.2 |
| RSI | RSI(14): 45.7 |
|||
| 52-week | High : | 3500.41 | Low : | 6.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACON ] has closed above bottom band by 24.2%. Bollinger Bands are 98.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 25 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.8 - 7.84 | 7.84 - 7.88 |
| Low: | 6.96 - 7.02 | 7.02 - 7.06 |
| Close: | 7.54 - 7.62 | 7.62 - 7.69 |
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Wed, 22 Oct 2025
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH - markets.businessinsider.com
Wed, 22 Oct 2025
Aclarion (Nasdaq: ACON) named Rising Star in Clinical Diagnostic Device at HLTH 2025 - Stock Titan
Mon, 13 Oct 2025
266M with low back pain — Aclarion Nociscan MR spectroscopy + AI identifies painful discs at ISPN - Stock Titan
Tue, 07 Oct 2025
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH - Sahm
Tue, 07 Oct 2025
Aclarion, Inc. Named Finalist in 2025 Digital Health Awards for Nociscan Technology - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 582340 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.12e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 988.5 % |
| Return on Equity (ttm) | -44.4 % |
| Qtrly Rev. Growth | 62950 % |
| Gross Profit (p.s.) | 53.97 |
| Sales Per Share | -62.66 |
| EBITDA (p.s.) | -11773 |
| Qtrly Earnings Growth | -12.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.13 |
| Price to Cash Flow | 0.44 |
| Dividend | 0 |
| Forward Dividend | 12640 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|